Ranbaxy Laboratories Ltd. may be getting most of the headlines, but a large portion of the Indian pharmaceutical sector is getting close attention from the Food & Drug Administration, now emboldened and energized with new inspection tools from the FDA Safety & Innovation Act, according to Elsevier Business Intelligence’s RPM Report
Using Warning Letters as a marker for the focus of inspection activity and the locus of problems found, India clearly moved to the top of FDA’s priority list for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?